LXRX Key Statistics, Chart & Performance
The current stock price of LXRX is 1.4 USD. In the past month the price decreased by -2.1%. In the past year, price increased by 98.55%.
LXRX Latest News, Press Relases and Analysis
LXRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About LXRX
Company Profile
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Company Info
LEXICON PHARMACEUTICALS INC
2445 Technology Forest Blvd, 11Th Floor
The Woodlands TEXAS 77381 US
CEO: Lonnel Coats
Employees: 103
Phone: 12818633000
LEXICON PHARMACEUTICALS INC / LXRX FAQ
What does LXRX do?
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Can you provide the latest stock price for LEXICON PHARMACEUTICALS INC?
The current stock price of LXRX is 1.4 USD. The price decreased by -1.41% in the last trading session.
What is the dividend status of LEXICON PHARMACEUTICALS INC?
LXRX does not pay a dividend.
What is the ChartMill rating of LEXICON PHARMACEUTICALS INC stock?
LXRX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does LEXICON PHARMACEUTICALS INC have?
LEXICON PHARMACEUTICALS INC (LXRX) currently has 103 employees.
What is the outstanding short interest for LEXICON PHARMACEUTICALS INC?
The outstanding short interest for LEXICON PHARMACEUTICALS INC (LXRX) is 6.87% of its float.
LXRX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LXRX. When comparing the yearly performance of all stocks, LXRX is one of the better performing stocks in the market, outperforming 94.7% of all stocks.
LXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LXRX. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative.
LXRX Financial Highlights
Over the last trailing twelve months LXRX reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 74.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.3% | ||
| ROE | -57.07% | ||
| Debt/Equity | 0.47 |
LXRX Forecast & Estimates
11 analysts have analysed LXRX and the average price target is 2.94 USD. This implies a price increase of 109.83% is expected in the next year compared to the current price of 1.4.
For the next year, analysts expect an EPS growth of 73.11% and a revenue growth 328.76% for LXRX